Molecular Vision 2009; 15:937-948 <>
Received 24 February 2009 | Accepted 23 April 2009 | Published 8 May 2009

Alteration of TLR3 pathways by glucocorticoids may be responsible for immunosusceptibility of human corneal epithelial cells to viral infections

Yuko Hara,1 Atsushi Shiraishi,2 Takeshi Kobayashi,2 Yuko Kadota,1 Yuji Shirakata,3 Koji Hashimoto,3 Yuichi Ohashi1

1Department of Ophthalmology, Ehime University School of Medicine, Shitsukawa, Japan; 2Department of Ophthalmology and Regenerative Medicine, Ehime University School of Medicine, Shitsukawa, Japan; 3Department of Dermatology, Ehime University School of Medicine, Shitsukawa, Japan

Correspondence to: Yuko Hara, Department of Ophthalmology, Ehime University School of Medicine Shitsukawa, Toon, Ehime 791-0295, Japan; Phone: 81-89-960-5361; FAX: 81-89-960-5364; email:


Purpose: The toll-like receptor 3 (TLR3) recognizes viral double-stranded RNA and its synthetic analog polyriboinosinic-polyribocytidylic acid (poly(I:C)), and the activation of TLR3 is known to induce the production of type I interferon (IFN) and inflammatory cytokines/chemokines. The purpose of this study was to determine the role played by innate responses to a herpes simplex virus 1 (HSV-1) infection of the corneal epithelial cells. In addition, we determined the effects of immunosuppressive drugs on the innate responses.

Methods: Cultured human corneal epithelial cells (HCECs) were exposed to poly(I:C), and the expressions of the mRNAs of the cytokines/chemokines macrophage-inflammatory protein 1 alpha (MIP1-α), macrophage-inflammatory protein 1 beta (MIP1-β), interleukin-6 (IL-6), interleukin-8 (IL-8), regulated on activation, normal T cell expressed and secreted (RANTES), Interferon-beta (IFN-β), and TLR3 were determined using real-time reverse transcription-polymerase chain reaction (RT-PCR). The effects of dexamethasone (DEX, 10-6 or 10-5 M) and cyclosporine A (CsA, 10-6 or 10-5 M) on the expression of these cytokines and TLR3 were also determined using real-time RT-PCR. Levels of MIP1-α, MIP1-β, IL-6, IL-8, RANTES, and IFN-β were measured using the enzyme-linked immunosorbent assay (ELISA). The activation of nuclear factor kappa B (NFκB) and interferon regulatory factor 3 (IRF3) in HCECs was assessed by immunohistochemical staining. The effects of DEX and CsA on HCECs exposed to HSV-1 (McKrae strain) were also examined.

Results: The expressions of MIP1-α, MIP1-β, IL-6, IL-8, RANTES, IFN-β, and TLR3 were up-regulated in HCECs exposed to poly(I:C). The poly(I:C)-induced expressions of IL-6 and IL-8 were down-regulated by both DEX and CsA, while the expressions of IFN-β and TLR3 were suppressed by DEX alone. Similarly, the poly(I:C)-induced activation of NFκB was decreased by both DEX and CsA, and the activation of IRF3 was reduced by DEX alone. When HCECs were inoculated with HSV-1, DEX led to a decrease in the expression of IL6, IFN-β, and TLR3, and an extension of plaque formation.

Conclusion: These results indicate that DEX may increase the susceptibility of HCECs to viral infections by altering the TLR3 signaling pathways.


The toll-like receptors (TLRs) are a family of innate immune receptors that recognize the conserved structures of microbes, termed pathogen-associated molecular patterns (PAMPs). The TLR system has been extensively studied in immune cells, e.g. in macrophages, and recent studies have demonstrated that epithelial cells also express TLRs. Thus, respiratory epithelial cells express TLR 1–10 [1,2], epidermal keratinocytes express TLR1, 2, 4, and 5 [3,4], intestinal epithelial cells express TLR1–4, 6, and 9 [5], and female reproductive tract epithelial cells express TLR1–9 [6]. In the eye, human corneal epithelial cells express TLR 1–7, 9, and 10 [7], and human conjunctival epithelial cells express TLR 1–6 and 9 [8].

The question then arises whether the TLRs play a role in the keratitis caused by the herpes simplex virus (HSV). It is known that treatment of stromal keratitis with topical acyclovir significantly reduces the number of patients who suffer serious visual impairment. However, keratitis often recurs in immunocompromised hosts or in individuals who receive steroid therapy for a long period of time. In fact, topical or systemic application of glucocorticoids results in the reactivation of herpes keratitis [9,10], and glucocorticoids are contraindicated for epithelial keratitis because they can worsen the clinical course to virus-induced geographic keratitis [11].

Recent studies have shown that a TLR3 ligand, which is a double-stranded RNA (dsRNA) can activate different types of epithelial cells, e.g. airway epithelial cells, female reproductive tract epithelial cells, and corneal epithelia cells [7,12,13]. TLR3 is the only TLR that does not interact with myeloid differentiation factor 88 (MyD88) as a signaling adaptor [14]. TLR3 interacts directly with the adaptor protein, Toll/interleukin-1 receptor (TIR) domain-containing adaptor inducing IFN-β (TRIF), which is also called the TIR-containing adaptor molecule (TICAM-1). TRIF/TICAM-1 activates the transcription factor NFκB and the interferon regulatory factor 3 (IRF3) [15,16]. The activation of NFκB leads to the production of inflammatory cytokines/chemokines, and the activation of IRF3 elicits anti-viral responses, especially through the production of type I IFN [15,17,18]. The production of type I IFN is the first line of defense against viral infections, and it acts by limiting the early replication of viruses [19,20]. Deonarain et al. [21] demonstrated that IFN-β is crucial for this process, because IFN-β-deficient mice are highly susceptible to viral infections.

TLR3 recognizes dsRNA and would not be expected to detect DNA from a DNA virus, such as HSV. However, it is known that most viruses synthesize dsRNA during their replication [22], and therefore TLR3 should be able to recognize HSV. Recently, Kariko et al. [23] reported that TLR3 is stimulated by cellular mRNA, and Ashkar et al. [24] reported that the delivery of ligands for TLR3, but not TLR4, protected against HSV-2 infections. Hayashi et al. [25] reported that herpes simplex virus 1 (HSV-1) elicited inflammatory cytokines via TLR3 and TLR9 in the corneal epithelial cells. Thus, corneal epithelial cells may play a role as the first line of defense against viral infection, including HSV infection, through the TLRs.

The purpose of this study was to determine the role played by innate responses in controlling HSV-1 infection of the corneal epithelial cells. In addition, we examined whether immunosuppressive drugs altered the HSV-1 infection of the cornea. We shall show that polyriboinosinic-polyribocytidylic acid (poly(I:C)), a TLR3 agonist, can induce anti-viral responses in corneal epithelial cells. However, these anti-viral responses can be altered by dexamethasone (DEX) and cyclosporine A (CsA).


Human subjects

All procedures on human subjects conformed to the tenets of the Declaration of Helsinki [26]. The experimental protocol for these experiments was approved by the Institutional Review Board of Ehime University.

Chemicals and cell cultures

All reagents used for the cell cultures were purchased from Invirogen (Carlsbad, CA). Primary human corneal epithelial cells (HCECs) were isolated from human corneoscleral buttons dissected from eyes acquired from an American Eye Bank(Sight Life Seattle WA) as reported [27]. Briefly, the buttons were carefully denuded of the endothelial cells and adherent iris. After digestion with 1.2 U/ml dispase at 4 ºC for 24 h, the loosened epithelial sheets were removed and dispersed into single cells by enzyme digestion with 0.1% trypsin and 0.02% EDTA. Then, the HCECs were cultured in serum-free modified MCDB 153 type II medium, supplemented with insulin (5 μg/ml), hydrocortisone (5×10-7 M), ethanolamine (0.1 mM), phosphoethanolamine (0.1 mM), Insulin-like growth factor-1 (IFG-1; 10 ng/ml), Epidermal growth factor (EGF; 0.1 ng/ml), and Ca2+ (0.06 mM). The medium was changed every 2 days.

To determine the effects of DEX and CsA on the poly(I:C)-induced expression of cytokines/chemokines, HCECs were cultured with hydrocortisone-free, modified MCDB 153 type II medium for 24 h, then incubated with 100 ng/ml of poly(I:C) in the presence or absence of DEX (10-6 or 10-5 M) or CsA (10-6 or 10-5 M). In the CsA control, CsA was substituted with 0.01% dimethyl sulfoxide (DMSO), which was also used to reconstitute the CsA. After 24 h of stimulation the cells and supernatants were collected.

Real-time PCR analysis

Total RNA was extracted from the cultured HCECs using RNeasy kit (Qiagen, Valencia, CA), and then reverse-transcribed using Omniscript Reverse Transcriptase (Qiagen) according to the manufacturer’s protocols. Real-time PCR was performed with the DyNAmo SYBR Green qPCR Kit (Finnzymes, Espoo, Finland) as follows: 95 ºC for 15 min; 40 cycles of denaturation at 95 ºC for 10 s; annealing at 60 ºC for 20 s; and extension at 72 ºC for 30 s using the OPticon 2 DNA Engine (BioRad, Hercules, CA). The primer pairs used for real-time PCR are listed in Table 1. The Ct values were determined by the Opticon 2 software, and the amount of each mRNA was calculated relative to the amount of Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) mRNA in the same samples [28]. Each run was completed with a melting curve analysis to confirm the specificity of the amplification and the absence of primer dimers.

Measurement of proinflammatory cytokines/chemokines production

The concentrations of MIP1-α, MIP1-β, IL-6, IL-8, RANTES, and IFN-β in the supernatants of the cultured HCECs were determined using an ELISA kit (R&D Systems, Minneapolis, MN) following the manufacturer’s protocols.

Immunostaining for NFκB and IRF3

HCECs were cultured on CultureSlides (BD Falcon, Bedford, MA) with 100 ng/ml of poly(I:C) in the presence or absence of DEX (10-5 M) or CsA (10-5 M) for 3 h. Cells were washed three times with phosphate-buffered saline (PBS), then fixed for 15 min in 3.2% paraformaldehyde (PFA)/PB. After washing with PBS, cells were permeabilized with 0.1% Triton X-100 for 5 min, followed by incubation with primary antibodies to NFκB p65 (0.2 μg/ml; Santa Cruz Biotechnology, Santa Cruz, CA) or to IRF3 (0.2 μg/ml; Santa Cruz Biotechnology) in 1% bovine serum albumin (BSA)/PBS at 4 ºC for 16 h. After washing with PBS, the slides were incubated with specific secondary antibodies, then incubated with appropriate fluorescein (FITC) conjugated antibodies (Pierce, Rockford, IL). Finally, the slides were coverslipped using an anti-fading mounting medium (Vector, Burlingame, CA). For the controls, sections were treated with normal rabbit immunoglobulin G (IgG), and no positive staining was detected with any of the antibodies.

Herpes simplex virus 1 (HSV-1) infection

Stocks of the McKrae strain of HSV-1 were propagated on African green monkey kidney (Vero) cells grown in complete Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin, and streptomycin. The titer of virus stocks was determined by the standard plaque assay on Vero cells, and titers were expressed as plaque-forming units (PFU)/ml. Stocks were stored at –70 ºC in 1 ml aliquots, and a fresh aliquot of stock virus was used for each experiment.

HCECs were cultured in a hydrocortisone-free, modified MCDB 153 type II medium for 24 h, and cultured in the presence or absence of DEX (10-5 M) or CsA (10-5 M) prior to exposure to HSV-1. For the plaque assay, HCECs were inoculated with HSV-1 at a multiplicity of infection (MOI) of 50 for 48 h, and the cells were then fixed with 10% formalin and stained with crystal violet. The area of the plaques was measured by Adobe Photoshop software (Adobe Systems Incorporated, San Jose, CA) to evaluate the efficiency of infection. The supernatants were also collected to evaluate the concentration of HSV-1 DNA by real-time PCR. To examine the participation of the TLR3 systems in signaling the HSV-1 infection on HCECs, the HCECs were pre-incubated with or without DEX, and then inoculated with HSV-1. To collect the cells before plaque formation, the time period from inoculation to testing was reduced to 24 h, and the inoculated dose increased to a MOI of 1,000, to allow detection of changes in inflammatory cytokines/chemokines. Therefore, HCECs were pre-incubated with or without DEX (10-5 M), followed by HSV-1 inoculation with a MOI of 1,000, and the cells collected for real-time PCR after 24 h.

Statistical analyses

Each experiment was repeated 3 times, and representative results are shown in the figures. Values are presented as means±standard deviations (SDs). Differences between the groups were determined by two-tailed paired t-tests. A p-value of <0.05 was considered to be statistically significant.


Poly(I:C)-induced TLR3 signaling pathway

To determine whether the TLR3/TRIF pathway is active in cultured HCECs, the HCECs were incubated with 100 ng/ml of poly(I:C) for 6, 12, and 24 h. Real time RT-PCR was then performed on the cells with primer pairs for MIP1-α, MIP1-β, IL-6, IL-8, RANTES, IFN-β, and TLR3. After stimulation by poly(I:C), the expression of the mRNA of MIP1-α, IL-6, IL-8, and RANTES were up-regulated as early as 6 h, and the level had increased 750 fold, 60 fold, 50 fold, and 10,000 fold, respectively, at 24 h. MIP1-β was also up-regulated at 12 h and reached about 400 fold at 24 h. IFN-β was up-regulated 9.9 fold within 6 h, which was maintained for 24 h (Figure 1). TLR3 was also up-regulated at 12 h, and the level had increased about 40 fold after 24 h (Figure 2A). The expressions of inflammatory cytokines/chemokines and TLR3 were not significantly altered without poly(I:C) stimulation (Figure 1 and Figure 2A).

The supernatants of the culture media were collected at 0, 6, 12, and 24 h, and the levels of MIP1-α, MIP1-β, IL-6, IL-8, RANTES, and IFN-β was evaluated using ELISA. The levels of MIP1-α, MIP1-β, and RANTES in the supernatant were elevated from undetectable levels at 0 h to 57.6 pg/ml, 630 pg/ml, and 1748.7 pg/ml, respectively, at 24 h after poly(I:C) stimulation. There was a slight but not significant elevation without poly(I:C) stimulation. The levels of IL-6 and IL-8 were slightly elevated without poly(I:C) stimulation, but were significantly elevated to 390 pg/ml and 920 pg/ml, respectively, at 24 h after poly(I:C) stimulation. The level of IFN-β was elevated to 43.8 pg/ml by poly(I:C) after 24 h, and no production of IFN-β was found without poly(I:C) stimulation (Figure 3).

Effect of DEX and CsA on TLR 3 signaling pathway

To determine whether DEX and CsA altered the expressions of the poly(I:C)-induced TLR3 and inflammatory cytokines/chemokines, HCECs were cultured with 100 ng/ml of poly(I:C) with or without DEX (10-6 or 10-5 M) or CsA (10-6 or 10-5 M). After 24 h, the cells and supernatants were collected, and the expression of the mRNAs and proteins of IL-6, IL-8, IFN-β, and TLR3 were evaluated by real-time PCR and ELISA.

Incubation with DEX down-regulated the poly(I:C)-induced expression of TLR3 mRNA about 0.5 fold with 10-6 M and 0.6 fold with 10-5 M of DEX, whereas no effect was found when incubated with CsA (Figure 2B,C).

Incubation with DEX down-regulated the poly(I:C)-induced expression of the mRNA of IL-6 about 0.4 fold with 10-6 M and 0.5 fold with 10-5 M of DEX (Figure 4). ELISA also showed that the poly(I:C) induced IL-6 production was decreased about 0.6 fold with 10-6 M and 0.5 fold with 10-5 M of DEX (Figure 5). The poly(I:C)-induced expressions of the mRNA and proteins of IL-8 were more significantly down-regulated by DEX, and the decrease was dose-dependent. Real-time PCR showed that the expression of the mRNA of IL-8 was down-regulated about 0.4 fold with 10-6 M and 0.3 fold with 10-5 M of DEX. ELISA also showed a reduced production of IL-8 protein of about 0.5 fold with 10-6 M and 0.4 fold with 10-5 M of DEX (Figure 4 and Figure 5). DEX also down-regulated the poly(I:C)-induced mRNA expression of IFN-β by about 0.5 fold with 10-6 M and 10-5 M of DEX and decreased IFN-β production by about 0.6 fold with 10-6 M and 0.5 fold with 10-5 M of DEX (Figure 4 and Figure 5).

The effect of CsA on the poly(I:C)-induced inflammatory cytokine/chemokine expression was not as extensive as with DEX. However, the poly(I:C)-induced IL-6 mRNA expression was down-regulated about 0.8 fold with 10-5 M of CsA, and ELISA showed that the poly(I:C) induced IL-6 production was reduced about 0.7 fold with 10-5 M of CsA (Figure 4 and Figure 5). The poly(I:C)-induced IL-8 mRNA expression was also down-regulated about 0.65 fold with 10-5 M of CsA (Figure 4), and ELISA showed a decrease in production of about 0.65 fold with 10-5 M of CsA (Figure 5). Interestingly, CsA had no effect on poly(I:C)-induced IFN-β mRNA expression or production (Figure 4 and Figure 5).

Immunohistochemical staining for NFκB and IRF3

The effect of DEX (10-5 M) or CsA (10-5 M) on the activation of NFκB and IRF-3 was determined immunohistochemically after 3 h of stimulation by poly(I:C). NFκB p65 and IRF-3 staining were weakly detected in the cytosol of cultured HCECs without poly(I:C) stimulation (Figure 6A,E), but activated NFκB p65 and IRF-3 were clearly detected in the nuclei of most of cultured HCECs 3 h after stimulation by poly(I:C; Figure 6B,F). After stimulation by poly(I:C) in the presence of DEX, NFκB p65 and IRF-3 were detected in the nuclei of some HCECs but only in the cytosol of other HCECs (Figure 6C,G). After stimulation by poly(I:C), NFκB p65 staining was detected in more HCEC nuclei after exposure to CsA than to DEX, but some HCECs were stained only in the cytosol when exposed to CsA (Figure 6D). IRF3 was detected only in the nuclei of cultured HCECs after 3 h of stimulation by poly(I:C) in the presence of CsA (Figure 6H).

Effect of DEX and CsA on Herpes simplex virus 1 (HSV-1) infection

To determine whether DEX and CsA affected the HSV-1 infection of HCECs, HCECs were cultured in the presence or absence of DEX (10-5 M) or CsA (10-5 M), and inoculated with HSV-1 at a MOI of 50. The plaque area was increased when HCECs were pre-incubated with DEX, but CsA had no effect on HSV-1 infection (Figure 7A). Real time PCR showed more HSV-1 DNA in the supernatant of DEX-exposed HCECs (Figure 7B).

In addition, we investigated the involvement of TLR3 signaling systems in HSV-1 infection of HCECs. Real-time PCR showed that the expressions of IL6, IFN-β, and TLR3 were down-regulated by DEX when HCECs were inoculated with HSV-1 (Figure 8). IL-6 and IL-8 were also down-regulated, although the decrease was not statistically significant for IL-8 (Figure 8).


Our results showed that poly(I:C), a TLR3 agonist, up-regulated the production of inflammatory cytokines/chemokines such as MIP1-α, MIP1-β, RANTES, IL-6, and IL-8, by activating NFκB. Incubation of HCECs with poly(I:C) also activated IRF3 followed by IFN-β production. The up-regulated expression of TLR 3 by poly(I:C) indicates that the TLR3/TRIF signaling pathways were most likely activated by poly(I:C) in HCECs. This is consistent with previous reports [1,15-17]. The cytokines and chemokines investigated are known to have powerful effects in recruiting immune cells and stimulating the maturation of dendritic cells [29-31]. Therefore, we suggest that corneal epithelial cells, when the TLR3s are activated de novo, are able to recruit and activate immune cells against viral infections.

Our results showed that DEX and CsA inhibit the poly(I:C)-induced NFκB activation and the subsequent production of inflammatory cytokines/chemokines. Earlier studies have shown that the concentration of topically applied reagents in tears sharply decreases to less than 1/100 of the original concentration by one hour after administration, and keeps decreasing until only trace levels remain [32,33]. The concentrations of DEX and CsA used in this study were 1/500 and 1/5,000 of the concentration used in eye drops in a clinical setting (0.05%), and so the results should be clinically applicable.

Glucocorticoids, potent inhibitors of immune responses, act through glucocorticoid receptors (GRs) to depress the activities of other DNA-bound transcription factors, such as activator protein 1(AP-1) and NFκB [34-37]. CsA is known to inhibit T cell activation and proliferation [38]. Recent studies have shown that the inhibitory effects of CsA result from interference in the degradation of inhibitory kappaB (IκB) and a reduction in the transcriptional activity of the classic NFκB signaling pathway [39,40]. Our immunohistochemical results showed that DEX and CsA inhibit the poly(I:C)-induced nuclear translocation of NFκB, and these findings are in accord with earlier reports. Thus, the inhibition of inflammatory cytokines/chemokines by DEX and CsA in HCECs may result from the inhibition of NFκB, and this may be one of the mechanisms responsible for the immunosuppressive property of DEX and CsA.

DEX and CsA have different effects on the activation of IRF3 and IFN-β production, and both are part of the TRIF/TICAM-1 TLR3 signaling pathways [15,17,18]. DEX inhibited the poly(I:C)-induced IRF3 activation and the subsequent IFN-β production, while CsA inhibited neither IRF3 activation nor IFN-β production. The exact mechanism of action of DEX and CsA on IRF3 has still not been determined, however Reily et al. [41] have identified the glucocorticoid receptor-interacting protein 1 (GRIP1) to be an IRF3-interacting protein that facilitates IRF3-mediated transcription. They showed that the GRIP1:IRF3 interaction is blocked by the activation of GRs [41]. Our finding that DEX inhibited the poly(I:C)-induced IRF3 activation in HCECs is in accord with their findings.

The different effects of DEX and CsA on the activation of IRF3 and IFN-β production might also be explained by their differing effects on the expression of TLR3. Because the IFN-responsive element (ISRE) is located on the human TLR3 promoter region, it has been suggested that IFNα/β induces the expression of TLR3 [42,43]. It has not been determined whether CsA regulates the IRFs or IFN, but our results showed no effect of CsA on IRF3 activation or on IFN-β production in HCECs.

The production of type I IFN is the first line of defense against viral infections, and it acts by limiting the early replication of viruses [19,20]. Deonarain et al. [21] demonstrated that IFN-β is crucial to this process because IFN-β-deficient mice were highly susceptible to viral infections. Our preliminary experiments showed that HSV infection was clearly depressed by poly(I:C) treatment prior to the HSV inoculation of the HCECs (data not shown). DEX treatment prior to HSV inoculation of HCECs led to the down-regulation of TLR3 and IFN-β followed by increased HSV-1 DNA and plaque formation. However, CsA did not interfere with the HSV-1 infection (data not shown). It is of interest to note that the anti-viral capabilities of corneal epithelial cells arise from their ability to produce IFN-β. Topical or systemic application of glucocorticoids results in the appearance of clinically active herpes keratitis, in which viral particles infect the corneal epithelial cells, leading to viral replication [9,10]. DEX has also been shown to increase the susceptibility of corneal epithelial cells to HSV-1 infection [44].

It has been known that TLR9 recognizes deoycytidylate-phosphate-deoxyguanosine (CpG) motifs in bacterial DNA, however, recent reports have demonstrated that TLR9 also recognizes CpG motifs in viral DNA, including HSV [24,45,46]. In addition, retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), including RIG-I, melanoma differentiation-associated gene 5 (Mda5), and Leishmania G-protein 2 (LGP2), have recently been identified as cytoplasmic proteins that recognize viral RNA [47,48]. The RLRs also activate NFκB and IRF3 following viral infection and poly(I:C) stimulation. RLRs-mediated signaling induced by dsRNA has been demonstrated in epidermal keratinocytes [49]. Our results showed an elevated production of inflammatory cytokines/chemokines that was associated with an up-regulated expression of TLR3, indicating that TLR3/TRIF signaling pathways are involved in the anti-viral response of HCECs. However, the presence of signaling cannot be fully accounted for by the TLR3/TRIF signaling pathway alone. It is possible that the TLR9 and RLRs pathways may also play a role in the production of inflammatory cytokines/chemokines, but we did not study the RLRs pathway. Further investigation will be needed to determine the exact mechanisms.

In summary, we have demonstrated that HCECs have ability to produce inflammatory cytokines/chemokines via the innate immune system, and these responses can be modified by DEX and CsA. DEX down-regulated both NFκB and IRF3, whereas CsA down-regulated only NFκB. This inhibition by DEX of IRF3 followed by IFN-β production may be another mechanism in the immunosusceptibility of HCECs to HSV infection. Thus, the innate corneal immune system may be involved in HSV infection of HCECs, and further studies to determine the function of the innate immune system might lead to new therapeutic agents, or the development of effective ways of preventing corneal infections.


This work was supported by a Grant-in-Aid for Young Scientists (B) 19791273 from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.


  1. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, Si-Tahar M. Involvement of Toll-like Receptor 3 in the Immune Response of Lung Epithelial Cells to Double-stranded RNA and Influenza A Virus. J Biol Chem. 2005; 280:5571-80. [PMID: 15579900]
  2. Muir A, Soong G, Sokol S, Reddy B, Gomez MI, Van Heeckeren A, Prince A. Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol. 2004; 30:777-83. [PMID: 14656745]
  3. Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol. 2003; 148:670-9. [PMID: 12752123]
  4. Pivarcsi A, Bodai L, Rethi B, Kenderessy-Szabo A, Koreck A, Szell M, Beer Z, Bata-Csorgoo Z, Magocsi M, Rajnavolgyi E, Dobozy A, Kemeny L. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol. 2003; 15:721-30. [PMID: 12750356]
  5. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000; 68:7010-7. [PMID: 11083826]
  6. Schaefer TM, Desouza K, Fahey JV, Beagley KW, Wira CR. Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology. 2004; 112:428-36. [PMID: 15196211]
  7. Ueta M, Hamuro J, Kiyono H, Kinoshita S. Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochem Biophys Res Commun. 2005; 331:285-94. [PMID: 15845391]
  8. Li J, Shen J, Beuerman RW. Expression of toll-like receptors in human limbal and conjunctival epithelial cells. Mol Vis. 2007; 13:813-22. [PMID: 17615542]
  9. Leopold IH, Sery TW. Epidemiology of Herpes Simplex Keratitis. Invest Ophthalmol. 1963; 2:498-503. [PMID: 14069759]
  10. McGill J, Fraunfelder FT, Jones BR. Current and proposed management of ocular herpes simplex. Surv Ophthalmol. 1976; 20:358-65. [PMID: 817407]
  11. Wilhelmus KR, Coster DJ, Donovan HC, Falcon MG, Jones BR. Prognosis indicators of herpetic keratitis. Analysis of a five-year observation period after corneal ulceration. Arch Ophthalmol. 1981; 99:1578-82. [PMID: 6793030]
  12. Schaefer TM, Fahey JV, Wright JA, Wira CR. Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly[I:C]. J Immunol. 2005; 174:992-1002. [PMID: 15634923]
  13. Sha Q, Truong-Tran AQ, Plitt JR, Beck LA, Schleimer RP. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol. 2004; 31:358-64. [PMID: 15191912]
  14. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006; 124:783-801. [PMID: 16497588]
  15. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol. 2003; 4:161-7. [PMID: 12539043]
  16. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003; 301:640-3. [PMID: 12855817]
  17. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001; 413:732-8. [PMID: 11607032]
  18. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, Akira S. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol. 2002; 169:6668-72. [PMID: 12471095]
  19. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science. 1994; 264:1918-21. [PMID: 8009221]
  20. Poli G, Biswas P, Fauci AS. Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Res. 1994; 24:221-33. [PMID: 7526793]
  21. Deonarain R, Alcami A, Alexiou M, Dallman MJ, Gewert DR, Porter AC. Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. J Virol. 2000; 74:3404-9. [PMID: 10708458]
  22. Jacobs BL, Langland JO. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology. 1996; 219:339-49. [PMID: 8638399]
  23. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem. 2004; 279:12542-50. [PMID: 14729660]
  24. Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis. 2004; 190:1841-9. [PMID: 15499542]
  25. Hayashi K, Hooper LC, Chin MS, Nagineni CN, Detrick B, Hooks JJ. Herpes simplex virus 1 (HSV-1) DNA and immune complex (HSV-1-human IgG) elicit vigorous interleukin 6 release from infected corneal cells via Toll-like receptors. J Gen Virol. 2006; 87:2161-9. [PMID: 16847112]
  26. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997; 277:925-6. [PMID: 9062334]
  27. Morita S, Shirakata Y, Shiraishi A, Kadota Y, Hashimoto K, Higashiyama S, Ohashi Y. Human corneal epithelial cell proliferation by epiregulin and its cross-induction by other EGF family members. Mol Vis. 2007; 13:2119-28. [PMID: 18079685]
  28. Rutledge RG, Cote C. Mathematics of quantitative kinetic PCR and the application of standard curves. Nucleic Acids Res. 2003; 31:e93 [PMID: 12907745]
  29. Arici A, Head JR, MacDonald PC, Casey ML. Regulation of interleukin-8 gene expression in human endometrial cells in culture. Mol Cell Endocrinol. 1993; 94:195-204. [PMID: 8224523]
  30. Jiang Y, Beller DI, Frendl G, Graves DT. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol. 1992; 148:2423-8. [PMID: 1348518]
  31. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science. 1993; 260:355-8. [PMID: 7682337]
  32. Limberg M, Bugge C. Tear concentrations of topically applied ciprofloxacin. Cornea. 1994; 13:496-9. [PMID: 7842707]
  33. Scuderi AC, De Lazzari A, Miano F, Zola P. Residence time of netilmicin in tears. Cornea. 2002; 21:48-50. [PMID: 11805507]
  34. Imai E, Miner JN, Mitchell JA, Yamamoto KR, Granner DK. Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. J Biol Chem. 1993; 268:5353-6. [PMID: 8449898]
  35. Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, Matsushima K. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem. 1994; 269:13289-95. [PMID: 8175759]
  36. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA. 1994; 91:752-6. [PMID: 8290595]
  37. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, Karin M. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell. 1990; 62:1205-15. [PMID: 2169352]
  38. Sigal NH, Dumont FJ, Cyclosporin A. FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol. 1992; 10:519-60. [PMID: 1375473]
  39. Kalli K, Huntoon C, Bell M, McKean DJ. Mechanism responsible for T-cell antigen receptor- and CD28- or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB. Mol Cell Biol. 1998; 18:3140-8. [PMID: 9584155]
  40. Marienfeld R, Neumann M, Chuvpilo S, Escher C, Kneitz B, Avots A, Schimpl A, Serfling E. Cyclosporin A interferes with the inducible degradation of NF-kappa B inhibitors, but not with the processing of p105/NF-kappa B1 in T cells. Eur J Immunol. 1997; 27:1601-9. [PMID: 9247567]
  41. Reily MM, Pantoja C, Hu X, Chinenov Y, Rogatsky I. The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J. 2006; 25:108-17. [PMID: 16362036]
  42. Heinz S, Haehnel V, Karaghiosoff M, Schwarzfischer L, Muller M, Krause SW, Rehli M. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem. 2003; 278:21502-9. [PMID: 12672806]
  43. Tanabe M, Kurita-Taniguchi M, Takeuchi K, Takeda M, Ayata M, Ogura H, Matsumoto M, Seya T. Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. Biochem Biophys Res Commun. 2003; 311:39-48. [PMID: 14575692]
  44. Weinstein BI, Schwartz J, Gordon GG, Dominguez MO, Varma S, Dunn MW, Southren AL. Characterization of a glucocorticoid receptor and the direct effect of dexamethasone on herpes simplex virus infection of rabbit corneal cells in culture. Invest Ophthalmol Vis Sci. 1982; 23:651-9. [PMID: 7129809]
  45. Ashkar AA, Bauer S, Mitchell WJ, Vieira J, Rosenthal KL. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol. 2003; 77:8948-56. [PMID: 12885911]
  46. Harandi AM. The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges. J Clin Virol. 2004; 30:207-10. [PMID: 15135735]
  47. Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell. 2006; 22:561-9. [PMID: 16762830]
  48. Yoneyama M, Fujita T. Function of RIG-I-like receptors in antiviral innate immunity. J Biol Chem. 2007; 282:15315-8. [PMID: 17395582]
  49. Kalali BN, Kollisch G, Mages J, Muller T, Bauer S, Wagner H, Ring J, Lang R, Mempel M, Ollert M. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. J Immunol. 2008; 181:2694-704. [PMID: 18684960]